Matrix to foucs on Mylan, may sell DocpharmaBS Reporter / Hyderabad February 28, 2008Hyderabad-based pharmaceutical major, Matrix Laboratories, ispursuing strategic alternatives for Docpharma, including a possible divestiture of the Docpharma business.Docpharma, a leading marketer and distributor of generic pharmaceuticals in Belgium, the Netherlands and Luxemburg (Benelux countries), was acquired by Matrix in 2005.Shortly following the acquisition of Docpharma, Matrix underwent significant activity including the acquisition of a 71.5% controlling interest by Mylan, a US-based generics pharmaceutical company. Since then, Matrix has realigned its strategic focus with Mylan to yield greater value for shareholders.In light of Mylan's acquisition of Merck Generics, Matrix will further refocus its business to reflect the importance of strategic arrangements with Mylan in support of its enlarged global platform, the company stated in a press release issued to the BSE on Thursday.Strategic alternatives for Docpharma, up to and including divestiture, is yet to be approved by the company's shareholders. Further details will be announced once the company has reached a definitive agreement, it added.
